This is a working overview of NR1D1, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-04 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
== Early life and education == Hagedorn was born in Copenhagen. His father was the captain of a coaster adapted for use as a folk high school ship where aspiring sailors received training in navigation as well as other subjects. Hagedorn attended Hesselager Latin School on Funen. In 1916, he began to study medicine at the University of Copenhagen. During his studies, he worked as an assistant for Carl Julius Salomonsen. He also assisted Christian Bohr.
=== EC 1.21.99 With unknown physiological acceptors === EC 1.21.99.1 EC 1.21.99.1: β-cyclopiazonate dehydrogenase EC 1.21.99.2: Now classified as EC 1.21.98.1, cyclic dehypoxanthinyl futalosine synthase. EC 1.21.99.3: thyroxine 5-deiodinase EC 1.21.99.4: thyroxine 5′-deiodinase EC 1.21.99.5: tetrachloroethene reductive dehalogenase
The retribution stoked renewed rebellion, which, combined with a weakened Spain, made possible a successful rebellion led by the Venezuelan-born Simón Bolívar, who finally proclaimed independence in 1819. The pro-Spanish resistance was defeated in 1822 in the present territory of Colombia and in 1823 in Venezuela. During the Independence War, between 250 and 400 thousand people died (12–20% of the pre-war population).
Sources: en.wikipedia.org
A practical consequence of redundancy is that some errors in the genetic code cause only a synonymous mutation, or an error that would not affect the protein because the hydrophilicity or hydrophobicity is maintained by equivalent substitution of amino acids (conservative mutation). For example, a codon of NUN (where N = any nucleotide) tends to code for hydrophobic amino acids, NCN yields amino acid residues that are small in size and moderate in hydropathy, and NAN encodes average size hydrophilic residues. These tendencies may result from the shared ancestry of the aminoacyl tRNA synthetases related to these codons. These variable codes for amino acids are allowed because of modified bases in the first base of the anticodon of the tRNA, and the base-pair formed is called a wobble base pair. The modified bases include inosine and the Non-Watson-Crick U-G basepair.
The yields of terpenes retrieved from these samples were higher than other species that also contain phenolic diterpenes, suggesting that high percentages of sesquiterpenes and diterpenes are an additional biomarker for Taxodioxylon gypsaceum.
T cells (also known as T lymphocytes) are an important part of the immune system and play a central role in the adaptive immune response. T cells can be distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on their cell surface. T cells are born from hematopoietic stem cells, found in the bone marrow. Developing T cells then migrate to the thymus gland to develop (or mature). T cells derive their name from the thymus. After migration to the thymus, getting stimulated by thymosin, the precursor cells mature into several distinct types of T cells. T cell differentiation also continues after they have left the thymus. Groups of specific, differentiated T cell subtypes have a variety of important functions in controlling and shaping the immune response. One of these functions is immune-mediated cell death, and it is carried out by two major subtypes: CD8+ "killer" (cytotoxic, Effector tumor antigen-specific T cells) and CD4+ "helper" T cells, each respectively named for the presence of proteins CD8 or CD4 on the cell surface. CD8+ T cells, also known as "killer T cells," are cytotoxic, referring to their ability to directly kill virus-infected cells and cancer cells. CD8+ T cells are also able to use small signalling proteins, known as cytokines, to recruit other types of cells when mounting an immune response. On the other hand, CD4+ T cells function as "helper cells." Unlike CD8+ killer T cells, the CD4+ helper T (TH) cells function by further activating memory B cells and cytotoxic T cells, which leads to a larger immune response.
Cartels have used public displays of violence, including videos of executions and street banners, to spread fear and assert control. They have also committed terrorist attacks. The 2008 Morelia grenade attacks killed eight and injured more than 100 civilians celebrating Independence Day. In 2011, Los Zetas carried out an arson attack on the Casino Royale in Monterrey, killing 52 civilians. Some see these efforts as intended to sap the morale of the Mexican government; others see them as an effort to let citizens know who is winning the war. Similarly, at least one dozen Mexican norteño musicians have been murdered. Most of the victims performed narcocorridos, folk songs that tell the stories of the Mexican drug trade. On July 10, 2008, the Mexican government announced plans to nearly double the size of its Federal Police force to reduce the role of the military in combating drug trafficking.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.